A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
<h4>Purpose</h4>This first-in-human study was designed to evaluate the pharmacokinetic (PK) equivalence between HD204 and the European Union (EU)-sourced bevacizumab, between HD204 and the United States of America (US)-sourced bevacizumab, and between EU-sourced and US-sourced bevacizuma...
Guardado en:
Autores principales: | Martin Demarchi, Pierre Coliat, Philippe Barthelemy, Roland Schott, Meher BenAbdelghani, Michael Kim, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Rui Xia Ang, Marie Paule Derde, Filip Deforce, Thierry Petit, Chris Schwabe, Chris Wynne, Lisa Soyeon Park, Xavier Pivot |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/45bef64f51cc46f89c05d51ff1082315 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bevacizumab-Induced Geographic Tongue
por: Marta Martinez-Garcia, et al.
Publicado: (2021) -
Bevacizumab in the treatment of ovarian cancer
por: Ramez N Eskander, et al.
Publicado: (2011) -
Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mary F Mulcahy
Publicado: (2008) -
Case of endophthalmitis following intravitreal injections of bevacizumab
por: Shinya Komori, et al.
Publicado: (2010) -
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo AE, et al.
Publicado: (2017)